Compare Hewlett Packard Enterprise Co (HPE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs ResMed Inc. — how do they compare? Hewlett Packard Enterprise Co trades at $71.6 (market cap $94.25B), while ResMed Inc. trades at $229.08 (market cap $31.89B). The key difference: Hewlett Packard Enterprise Co is far larger — about 3× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and ResMed Inc. for 51 Days on average.
| HPE | RMD | |
|---|---|---|
Market Cap | $94.25B | $31.89B |
Volume | 16,060,854 | 618,314 |
Sector | Technology | Health |
52-Week High | $72.12 | $277.88 |
52-Week Low | $20.01 | $182.82 |
Typical Hold Time | 33 Days | 51 Days |
Enterprise Value | $108.28B | $31.24B |
Dividend Yield | 0.8% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock is trading at $72.12, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.11 surpassing the $0.932 estimate. The company secured a $1.2 billion AI server order from Vultr and raised its networking outlook, fueling bullish technical signals and positive analyst sentiment.
The outlook remains optimistic due to AI-driven growth and raised revenue targets, but risks include high valuation multiples and volatile cash flows. With a consensus price target of $70.35, slightly below the current price, the stock faces potential near-term resistance despite strong fundamentals and institutional upgrades.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
